ERBB2 and breast carcinoma: Although the oncogenic activity of the L755 mutations was not demonstrated, Bose et al reported that mutated L755 breast cancer cell lines were less sensitive to the reversible dual EGFR/ERBB2 inhibitor lapatinib but may be sensitive to irreversible dual EGFR/ERBB2 inhibitors such as neratinib [14, 15].